ANP (Atrial Natriuretic Peptide) vs KPV
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
ANP (Atrial Natriuretic Peptide)
ANP is a cardiac hormone released by atrial myocytes in response to stretch. It promotes natriuresis, diuresis, and vasodilation, playing key roles in blood pressure and fluid regulation.
Full details →KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →Side-by-Side Comparison
| Aspect | ANP (Atrial Natriuretic Peptide) | KPV |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 200 mcg–500 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to natriuretic peptide receptors (NPR-A) to activate guanylyl cyclase, producing cGMP. This leads to vasodilation, increased kidney filtration, and inhibition of the renin-angiotensin-aldosterone system. | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. |
| Typical Dosage | Clinical use: Carperitide (recombinant ANP) used in Japan for acute heart failure at 0.1mcg/kg/min IV infusion. | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. |
| Administration | Intravenous infusion only for clinical applications. Short half-life (~2 minutes) requires continuous administration. | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. |
| Side Effects | Hypotension (dose-limiting), headache, nausea, and potential arrhythmias at high doses. | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. |
| Best For |
What They Have in Common
ANP (Atrial Natriuretic Peptide), KPV are both commonly used for:
Key Differences
Unique to KPV:
Which Has Stronger Evidence?
- Recovery & Healing: ANP (Atrial Natriuretic Peptide) has stronger research support.
| Goal | ANP (Atrial Natriuretic Peptide) | KPV |
|---|---|---|
| Recovery & Healing | medium | low |
Key Studies
ANP (Atrial Natriuretic Peptide)
- Atrial natriuretic peptide (ANP) modulates stress-induced autophagy in endothelial cells.
Biochimica et biophysica acta. Molecular cell research, 2025
- C-atrial natriuretic peptide (ANP)(4-23) attenuates renal fibrosis in deoxycorticosterone-acetate-salt hypertensive mice.
Experimental cell research, 2023
- Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach.
Hypertension (Dallas, Tex. : 1979), 2021
KPV
- KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling.
Tissue & cell, 2026
- KPV and RAPA Self-Assembled into Carrier-Free Nanodrugs for Vascular Calcification Therapy.
Advanced healthcare materials, 2024
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.
Acta biomaterialia, 2022
Ready to Learn More?
Looking for trusted sources?